by Anderson Triggs | Sep 22, 2026 | Anti-Aging News, Clinical Laboratory Analysis, Sterile & Non-Sterile Compounding, Testosterone & Anti-Aging Therapy
WEBINAR TOMORROW September 23, 2026 1 PM EST / 10 AM PST I am excited to announce my upcoming webinar on peptide therapy, where we will take a practical look at the regulatory landscape, clinical applications, diagnostic considerations, patient selection, monitoring,...
by Anderson Triggs | Jul 23, 2026 | Anti-Aging News, Sterile & Non-Sterile Compounding, Testosterone & Anti-Aging Therapy
Here’s What That Actually Means The conversation around peptides is changing. On July 23 and 24, 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) will meet to review several of the most well-known peptides in regenerative and longevity...
by Anderson Triggs | Mar 19, 2026 | Anti-Aging News, Sterile & Non-Sterile Compounding
The Next Evolution in Regenerative Peptide Therapy When it comes to advanced recovery and regenerative medicine, few compounds have generated as much interest as BPC-157. Known for its powerful effects on muscle, tendon, ligament, and gastrointestinal healing, BPC-157...
by Anderson Triggs | Oct 29, 2024 | Anti-Aging News, Sterile & Non-Sterile Compounding
On October 22, 2024, Novo Nordisk asked the FDA to add semaglutide to the demonstrably difficult to compound list. The Food and Drug Administration is proposing to establish criteria for the lists of drug products or categories of drug products that present...
by Anderson Triggs | Oct 14, 2024 | Anti-Aging News, Sterile & Non-Sterile Compounding
The FDA stirred enormous controversy when, without much notice, they placed some of the most popular peptides on their category 2 list, which disallows the compounding with these bulk substances also known as (APIs) Active Pharmaceutical Ingredients. Many of the...
by Anderson Triggs | Oct 13, 2024 | Anti-Aging News, Sterile & Non-Sterile Compounding
This week the pharmacy compounding, weight loss and anti-aging communities have been abuzz from the October 2, 2024 announcement from the FDA and Eli Lilly that they are removing both of the brand name tirzepatide blockbuster drugs, Mounjaro® and Zepbound® from the...
